2025-03-09 - Analysis Report
## Intuitive Surgical Inc. (ISRG) Stock Review

**0. Key Figures:**

* **Cumulative Return (ISRG):** 273.34%
* **Cumulative Return (VOO):** 108.62%
* **Return Difference:** 164.7%
* **Relative Divergence:** 74.6% (Indicates ISRG significantly outperformed VOO historically,  relative to its past performance range)
* **Current Price:** $518.26
* **5-Day Moving Average:** $549.96
* **20-Day Moving Average:** $579.35
* **60-Day Moving Average:** $563.64
* **RSI:** 25.29 (Suggests oversold conditions)
* **PPO:** -1.37 (Indicates bearish momentum)
* **20-Day Relative Divergence Change:** -14.9% (Short-term bearish trend)
* **Expected Return (vs. S&P 500):** 33.7% (Long-term, 2+ years)

**1. Company Overview and Performance Comparison:**

Intuitive Surgical Inc. is a leading medical device company specializing in robotic-assisted surgery systems.  ISRG has significantly outperformed the S&P 500 (VOO) with a cumulative return of 273.34% compared to VOO's 108.62%. The substantial difference of 164.7% highlights ISRG's strong historical performance.  The relative divergence of 74.6% shows that this outperformance is considerable within the historical context of the two assets' relative performance.

**Alpha and Beta Analysis:**

The provided data shows consistently high CAGR (Compound Annual Growth Rate) for ISRG over the past several years, ranging from 71% to 167%.  The Alpha values indicate periods of outperformance against the market (positive alpha), particularly in recent years. Beta values are quite high, suggesting significant market sensitivity.  The maximum drawdown (MDD) varies across periods, reflecting the inherent volatility of the stock.  The significant market capitalization consistently increases across years.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 77.0% | 7.3% | 49.0% | -0.0 | 43.4 |
| 2016-2018  | 89.0% | 8.9% | 71.0% | 0.0 | 56.9 |
| 2017-2019  | 93.0% | 9.8% | 63.0% | 0.5 | 70.3 |
| 2018-2020  | 71.0% | 9.8% | 43.0% | 0.2 | 97.3 |
| 2019-2021  | 113.0% | 9.8% | 42.0% | 0.2 | 128.2 |
| 2020-2022  | 21.0% | 20.6% | 12.0% | 0.2 | 94.6 |
| 2021-2023  | 19.0% | 20.6% | -4.0% | 1.0 | 120.3 |
| 2022-2024  | 128.0% | 20.4% | 95.0% | 1.0 | 186.2 |
| 2023-2025  | 167.0% | 9.9% | 118.0% | 0.8 | 184.8 |


**2. Recent Price Action:**

The current price of $518.26 is below its 5-day ($549.96), 20-day ($579.35), and 60-day ($563.64) moving averages, indicating a short-term downtrend. The recent price drop of $19.31 (from $538.57) is significant.


**3. Technical Indicators and Expected Return:**

The RSI of 25.29 suggests the stock is oversold, potentially indicating a buying opportunity. However, the negative PPO (-1.37) suggests bearish momentum. The recent 20-day relative divergence change of -14.9% confirms a short-term bearish trend. The significant price drop reflects a potential negative market event.  A 33.7% expected return over the long term (2+ years) against the S&P 500 indicates strong potential for continued outperformance, but this is merely a prediction and carries inherent risk.


**4. Recent Earnings Analysis:**

Earnings show a generally upward trend in both EPS and revenue, although there's some fluctuation quarter to quarter.

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2024-10-18 | 1.59 | 2.04 B$    |
| 2024-07-19 | 1.48 | 2.01 B$    |
| 2024-04-19 | 1.54 | 1.89 B$    |
| 2023-10-20 | 1.18 | 1.74 B$    |
| 2024-10-18 | 1.18 | 1.74 B$    | *(Duplicate entry, likely an error)*


**5. Financial Information:**

The financial information shows strong revenue growth and consistently high profit margins, indicating a healthy and profitable business.  ROE (Return on Equity) fluctuates but remains generally positive, suggesting effective utilization of shareholder equity.

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $2.41B | 68.04% |
| 2024-09-30 | $2.04B | 67.41% |
| 2024-06-30 | $2.01B | 68.30% |
| 2024-03-31 | $1.89B | 65.87% |
| 2023-12-31 | $1.93B | 66.24% |

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-12-31 | $16.43B | 4.17% |
| 2024-09-30 | $15.58B | 3.63% |
| 2024-06-30 | $14.71B | 3.58% |
| 2024-03-31 | $13.96B | 3.90% |
| 2023-12-31 | $13.31B | 4.56% |


**6. Overall Analysis:**

ISRG has a strong track record of outperformance compared to the S&P 500.  While recent price action suggests a short-term bearish trend,  the company's financial health (high revenue, profit margins, and generally positive ROE) remains strong.  The oversold RSI suggests potential for a rebound, but the negative PPO and the significant recent price drop warrant caution.  Long-term investors might see the current price as an attractive entry point considering the company's long-term growth potential and the high expected return relative to the S&P 500,  but this should be considered alongside a broader risk assessment.  Further investigation into the reasons for the recent price drop is crucial before making any investment decisions.  The duplicated data point in the earnings report should also be investigated and clarified for a more accurate analysis.
